1. OP0090 EFFICACY OF SUBCUTANEOUS TANEZUMAB FOR THE TREATMENT OF CHRONIC LOW BACK PAIN: AN ANALYSIS OF BRIEF PAIN INVENTORY-SHORT FORM SCORES FROM A 56-WEEK, RANDOMIZED, PLACEBO- AND TRAMADOL-CONTROLLED, PHASE 3 TRIAL. (2nd June 2020) Authors: Markman, J.; Perrot, S.; Ohtori, S.; Schnitzer, T.; Beydoun, S.; Viktrup, L.; Yang, R.; Bramson, C.; West, C.; Verburg, K. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 59 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Pooled efficacy and safety from phase 3 placebo-controlled studies of Tanezumab in patients with osteoarthritis. (April 2015) Authors: Tive, L.; Radin, D.; Bello, A.; Brown, M.; West, C.; Verburg, K. Journal: Osteoarthritis and cartilage Issue: Volume 23(2015)Supplement 2 Page Start: A355 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Postoperative outcome of patients who underwent total joint replacement during the tanezumab phase 3 osteoarthritis development program: a 24-week observational study. Issue 1 (April 2020) Authors: Mont, M.A.; Carrino, J.A.; Shafiei, F.; Nemeth, M.; Burr, A.; Yamabe, T.; Viktrup, L.; West, C.R.; Brown, M.T.; Verburg, K. Journal: Osteoarthritis and cartilage Issue: Volume 28:Issue 1(2020)supplement Page Start: S29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Subcutaneous tanezumab 2.5 MG or 5 MG for patients with osteoarthritis of the knee or hip: onset and maintenance of efficacy over 24 weeks. Issue 1 (April 2020) Authors: Berenbaum, F.; Langford, R.; Perrot, S.; Miki, K.; Blanco, F.J.; Yamabe, T.; Isogawa, N.; Araki, S.; Junor, R.; Carey, W.; Viktrup, L.; West, C.R.; Brown, M.T.; Verburg, K. Journal: Osteoarthritis and cartilage Issue: Volume 28:Issue 1(2020)supplement Page Start: S144 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗